2021-11
(November 28, 2021 - Hong Kong) Grand Pharmaceutical Group Limited (“GP (HK)” or the “Company”, together with its subsidiaries, the “Group”, stock code: 00512) is pleased to announce that the Group recently has entered into equity investment and product introduct...
2021-10
(October 18,2021 - Hong Kong) China Grand Pharmaceutical and Healthcare Holdings Limited (“GP (HK)” or the “Company”, together with its subsidiaries, the “Group”, stock code: 00512) is pleased to announce that Hubei Grand Life Science & Technology Co., Ltd. (&...
(October 20, 2021 - Hong Kong) China Grand Pharmaceutical and Healthcare Holdings Limited (“GP (HK)” or the “Company”, together with its subsidiaries, the “Group”, stock code: 00512) is pleased to announce that after the Group submitted the investigational new dru...
(November 9, 2021 - Hong Kong) China Grand Pharmaceutical and Healthcare Holdings Limited (“GP (HK)” or the “Company”, together with its subsidiaries, the “Group”, stock code: 00512) is pleased to announce that the global innovative drug STC3141, which is develope...
2021-08
Financial Highlights: The Group results remained strong growth for 1H 2021, it recorded revenue of approximately HK$4,566.5 million. During the Period, representing an increase of approximately 40.3% as compared to the corresponding period in 2020. The total profit for the period attributable to ow...
(August 6, 2021 - Hong Kong) China Grand Pharmaceutical and Healthcare Holdings Limited (“GP (HK)” or the “Company”, together with its subsidiaries, the “Group”, stock code: 00512) is pleased to announce that the Group has entered into strategic cooperation with U...
(August 2, 2021 - Hong Kong) China Grand Pharmaceutical and Healthcare Holdings Limited (“GP (HK)” or the “Company”, together with its subsidiaries, the “Group”, stock code: 00512) is pleased to announce that the Group and FastWave Medical Inc (“FastWave&rdq...
2021-07
(July 27, 2021 - Hong Kong) China Grand Pharmaceutical and Healthcare Holdings Limited (“GP (HK)” or the “Company”, together with its subsidiaries, the “Group”, stock code: 00512) is pleased to announce that for the six months ended 30 June 2021, it is expected th...
P (HK)’s Associate OncoSec Enters into A Collaboration Agreement with Merck to Conduct a Global Phase III Study in Advanced Metastatic Melanoma. The R&D of TAVO™ Records Landmark Progress, Continuing to Consolidate the Strategic Planning in Anti-Tumor Immunology Field (July 8, 2021 ...
GP(HK) Global Innovative RDC TLX250-CDX Dosed the First Patient with the Expanding Indication in Australia, and the Self-developed “Tadalafil Tablets” is Granted a Drug Registration Certificate, Continuously Improving Research Strength and Enriching Its Product Pipelines (July 7, 2021 -...
YOU WANT TO
